Repligen Corp Files 8-K on Operations and Financials

Ticker: RGEN · Form: 8-K · Filed: Jul 30, 2024 · CIK: 730272

Repligen Corp 8-K Filing Summary
FieldDetail
CompanyRepligen Corp (RGEN)
Form Type8-K
Filed DateJul 30, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: operations, financials, reporting

Related Tickers: RGEN

TL;DR

Repligen dropped an 8-K on July 30th detailing their financials. Check it out.

AI Summary

Repligen Corporation filed an 8-K on July 30, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing details the company's status as a biological products manufacturer incorporated in Delaware.

Why It Matters

This filing provides crucial updates on Repligen's financial performance and operational status, which can influence investor decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for operational and financial reporting, not indicating any unusual risks.

Key Players & Entities

  • REPLIGEN CORP (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • 000-14656 (company_id) — Commission File Number
  • 04-2729386 (company_id) — I.R.S. Employer Identification No.
  • 41 Seyon Street , Bldg. 1 , Suite 100 , Waltham , MA 02453 (address) — Principal executive offices
  • (781) 250-0111 (phone_number) — Registrant's telephone number

FAQ

What specific financial results are detailed in this 8-K filing?

This 8-K filing is a notification of the results of operations and financial condition, and includes financial statements and exhibits, but the specific financial figures are not detailed in the provided text.

When was this 8-K report filed?

The report was filed on July 30, 2024.

What is Repligen Corporation's primary business sector?

Repligen Corporation is in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.

Where is Repligen Corporation headquartered?

Repligen Corporation's principal executive offices are located at 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is REPLIGEN CORPORATION.

Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-30 07:46:52

Key Financial Figures

  • $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Date: July 30, 2024 By: /s/ Tony J. Hunt Tony J. Hunt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.